Developing Small Molecule Therapeutics for Ebola Hemorrhagic Fever Virus (Ricardo Carrion, Jr., Co-PI)

Ebola virus causes highly lethal viral hemorrhagic fever syndrome and has been classified as a Category A bioweapons agents by the Centers for Disease Control and Prevention (CDC). It can be used as a potential biological weapon due to their ease of dissemination, person-to person transmissibility and stability in aerosolized form. There is no effective vaccine or antivirals against Ebola virus infection in humans. Our overall goal is to discover and develop small molecule therapeutic agents against Ebola virus to respond to natural outbreaks of Ebola virus infection and to counter potential acts of bioterrorism